The best nootropic peptides, and where the Russian data stands
Most peptide nootropics are Russian pharmaceuticals with registration there and little Western trial data. That is not nothing, but it is not the same as an FDA approval, and the ranking reflects it.
Quick answer
| # | Compound | Class | Evidence | Reported range | Status |
|---|---|---|---|---|---|
| 1 | Cerebrolysin | Nootropic & neuro | Clinical trials | 5-30 g | Research only |
| 2 | Semax | Nootropic & neuro | Preliminary human | 300-900 mcg | Research only |
| 3 | Selank | Nootropic & neuro | Preliminary human | 250-750 mcg | Research only |
| 4 | N-Acetyl Semax Amidate | Nootropic & neuro | Anecdotal only | 100-300 mcg | Research only |
The ranking
Approved across Europe and Asia for dementia and stroke, with around forty clinical trials. A porcine brain hydrolysate rather than a defined molecule. The most clinically documented compound on this list by a wide margin.
Material for this compound is sold for laboratory research only. It is not manufactured, tested or labelled for human administration.
On the Russian essential medicines list for stroke and cognitive disorders. An ACTH fragment analog that raises BDNF. Western trial data is limited, but it is a registered pharmaceutical with a defined mechanism.
Material for this compound is sold for laboratory research only. It is not manufactured, tested or labelled for human administration.
Registered in Russia as an anxiolytic without sedation or dependence. Modulates enkephalin metabolism. Six small human trials. The best-documented peptide for anxiety rather than cognition specifically.
Material for this compound is sold for laboratory research only. It is not manufactured, tested or labelled for human administration.
Acetylated and amidated Semax, plausibly longer-acting. The potency claims trace to vendor marketing, not to any published comparison. It ranks on being Semax, not on being better than it.
Material for this compound is sold for laboratory research only. It is not manufactured, tested or labelled for human administration.
What we left out, and why
Head-to-head comparisons
References for the compounds in this guide
- Update on Neuroprotection after Traumatic Brain Injury.CNS Drugs 2025.PubMed 40087248 · doi:10.1007/s40263-025-01173-9
- Cerebrolysin for vascular dementia.Cochrane Database Syst Rev 2019.PubMed 31710397 · doi:10.1002/14651858.CD008900.pub3
- Cerebrolysin for acute ischaemic stroke.Cochrane Database Syst Rev 2020.PubMed 32662068 · doi:10.1002/14651858.CD007026.pub6
- Cerebrolysin for acute ischaemic stroke.Cochrane Database Syst Rev 2017.PubMed 28430363 · doi:10.1002/14651858.CD007026.pub5
- Cerebrolysin for acute ischaemic stroke.Cochrane Database Syst Rev 2016.PubMed 27918088 · doi:10.1002/14651858.CD007026.pub4
- Cerebrolysin for acute ischaemic stroke.Cochrane Database Syst Rev 2015.PubMed 26083192 · doi:10.1002/14651858.CD007026.pub3
- Therapeutic strategies in vascular cognitive impairment: A systematic review and meta-analysis.Alzheimers Dement 2025.PubMed 41198594 · doi:10.1002/alz.70840
- [Cognitive impairment in post-traumatic stress disorder].Zh Nevrol Psikhiatr Im S S Korsakova 2024.PubMed 38884432 · doi:10.17116/jnevro202412405169
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.J Am Acad Orthop Surg Glob Res Rev 2026.PubMed 41490200 · doi:10.5435/JAAOSGlobal-D-25-00236
- Pharmacological Aspects of Neuro-Immune Interactions.Curr Pharm Des 2018.PubMed 28875850 · doi:10.2174/1381612823666170829135115
- [Prospects for use of short peptides in pharmacotherapeutic correction of Alzheimer's disease.].Adv Gerontol 2024.PubMed 38944767
- [Evolution of the stress concept].Vestn Ross Akad Med Nauk 2008.PubMed 19140465
- [The efficacy of semax in the tretament of patients at different stages of ischemic stroke].Zh Nevrol Psikhiatr Im S S Korsakova 2018.PubMed 29798983 · doi:10.17116/jnevro20181183261-68
- [POSSIBLE ROLE OF TRANSTHYRETIN IN THE BIOLOGICAL MECHANISM OF THE REGULATORY PEPTIDE NEUROPROTECTION.].Mol Gen Mikrobiol Virusol 2016.PubMed 30383932
- Modulation of neuropathological pathways by bioactive peptides and proteins/polypeptides: Targeting oxidative stress in neurodegenerative diseases.Neuropeptides 2025.PubMed 41004910 · doi:10.1016/j.npep.2025.102563
- [Place of oligopeptide H-Met-Glu-His-Phe-Pro-Gly-Pro-OH in the therapy and rehabilitation of patients with ischemic stroke].Zh Nevrol Psikhiatr Im S S Korsakova 2024.PubMed 39166935 · doi:10.17116/jnevro202412408256
- Tuftsin - Properties and Analogs.Curr Med Chem 2017.PubMed 28745220 · doi:10.2174/0929867324666170725140826
- Anaesthesia and circulating blood volume.Eur J Anaesthesiol 2005.PubMed 15892402 · doi:10.1017/s0265021505000438
- [Optimization of the treatment of anxiety disorders with selank].Zh Nevrol Psikhiatr Im S S Korsakova 2015.PubMed 26356395 · doi:10.17116/jnevro20151156133-40
- [A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders].Zh Nevrol Psikhiatr Im S S Korsakova 2014.PubMed 25176261
- Low dosage lithium augmentation in venlafaxine resistant depression: an open-label study.Psychiatriki 2012.PubMed 22796912
- [Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia].Zh Nevrol Psikhiatr Im S S Korsakova 2008.PubMed 18454096
- [Comparison of anticoagulant effects of regulatory proline-containing oligopeptides. Specificity of glyprolines, semax, and selank and potential of their practical application].Izv Akad Nauk Ser Biol 2006.PubMed 16634437
- [Neuroprotective effects of peptides bioregulators in people of various age].Adv Gerontol 2013.PubMed 24738258
Literature retrieved from PubMed on October 16, 2026, favouring human studies and reviews. Numbered markers in the text show which paper supports which statement; uncited entries are background reading.